メチシリン耐性黄色ブドウ球菌(MRSA)市場:現在・未来プレイヤー

◆英語タイトル:Methicillin-Resistant Staphylococcus aureus (MRSA) - Current and Future Players
◆商品コード:GDHC1046FPR
◆発行会社(調査会社):GlobalData
◆発行日:2015年12月16日
◆ページ数:125
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,995 ⇒換算¥332,445見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,990 ⇒換算¥664,890見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD8,985 ⇒換算¥997,335見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Methicillin-Resistant Staphylococcus aureus (MRSA) – Current and Future Players
Summary

GlobalData has released its pharma report, “Methicillin-Resistant Staphylococcus aureus (MRSA) – Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing MRSA Market. The report identifies and analyses the key companies shaping and driving the global MRSA market. The report provides insight into the competitive MRSA landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Investigation of current and future market competition for MRSA
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of MRSA sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving MRSA market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global MRSA market landscape? Identify, understand and capitalize

【レポートの目次】

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Market Outlook
3.1 Global Markets
3.1.1 Forecast
3.1.2 Drivers and Barriers – Global Issues
4 Current and Future Players
4.1 Overview
4.2 Trends in Corporate Strategy
4.3 Company Profiles – Current Players
4.3.1 Pfizer
4.3.2 Merck
4.3.3 Allergan
4.3.4 The Medicines Company
4.3.5 Theravance Biopharma
4.3.6 Basilea Pharmaceutica
4.3.7 Sanofi
4.4 Additional Companies with Promising Pipeline Products
4.4.1 Melinta Therapeutics
4.4.2 Cempra Pharmaceuticals
4.4.3 Paratek Pharmaceuticals
4.4.4 Kyorin Pharmaceutical
4.4.5 Nabriva Therapeutics
4.4.6 Debiopharm International
4.4.7 Cellceutix Corporation
5 Appendix
5.1 Bibliography
5.2 Abbreviations
5.3 Methodology
5.4 Forecasting Methodology
5.4.1 Hospitalized MRSA Patients
5.4.2 Percentage of Drug-Treated MRSA Patients
5.4.3 Drugs Included in Each Therapeutic Class
5.4.4 Launch, Label Expansion, and Patent Expiry Dates
5.4.5 General Pricing Assumptions
5.4.6 Individual Drug Assumptions
5.4.7 Generic Erosion
5.4.8 Pricing of Pipeline Agents
5.5 Primary Research – KOLs Interviewed for This Report
5.6 Primary Research – Prescriber Survey
5.7 About the Authors
5.7.1 Author and Therapy Area Director
5.7.2 Author
5.7.3 Epidemiologist
5.7.4 Global Director of Therapy Analysis and Epidemiology
5.7.5 Global Head of Healthcare
5.8 About GlobalData
5.9 Disclaimer

1.1 List of Tables
Table 1: Global Sales Forecasts ($m) for MRSA Therapeutics, 2014-2024
Table 2: MRSA Therapeutics Market - Global Drivers and Barriers, 2014-2024
Table 3: Key Companies in the MRSA Marketplace in the 7MM, 2015
Table 4: Pfizer’s MRSA Portfolio Assessment, 2015
Table 5: Merck’s MRSA Portfolio Assessment, 2015
Table 6: Allergan’s MRSA Portfolio Assessment, 2015
Table 7: The Medicines Company’s MRSA Portfolio Assessment, 2015
Table 8: Theravance Biopharma’s MRSA Portfolio Assessment, 2015
Table 9: Basilea Pharmaceutica’s MRSA Portfolio Assessment, 2015
Table 10: Sanofi’s MRSA Portfolio Assessment, 2015
Table 11: Companies with Promising Pipeline Candidates for MRSA in the 7MM, 2015
Table 12: Key Historical and Projected Launch Dates for MRSA Across the 7MM
Table 13: Key Historical and Projected Label Expansion Dates for MRSA Across the 7MM
Table 14: Key Historical and Projected Patent Expiry Dates for MRSA Across the 7MM
Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Global Sales for MRSA Therapeutics by Country, 2014 and 2024
Figure 2: Global Sales for MRSA Therapeutics by Region, 2014-2024
Figure 3: Global Sales for MRSA Therapeutics by Drug Class, 2014 and 2024
Figure 4: Global Sales for MRSA Therapeutics by Infection Site, 2014-2024
Figure 5: Global Sales for Branded MRSA Products by Company, 2014 and 2024
Figure 6: Company Portfolio Gap Analysis in MRSA, 2014-2024

【掲載企業】

Pfizer
Merck
Allergan
The Medicines Company
Theravance Biopharma
Basilea Pharmaceutica
Sanofi

★調査レポート[メチシリン耐性黄色ブドウ球菌(MRSA)市場:現在・未来プレイヤー]販売に関する免責事項
★調査レポート[メチシリン耐性黄色ブドウ球菌(MRSA)市場:現在・未来プレイヤー]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆